Cannabis firm Cannara Biotech's Q4 revenue rises on market expansion

Cannara Biotech

24/11/2025 12:11

Overview

Cannara fiscal 2025 revenue rises 31% yr/yr to C$107.3 mln

Adjusted EBITDA for fiscal 2025 grows 86% yr/yr to C$28.1 mln

Company expands national market share to 3.81%, up 32% yr/yr

Outlook

Cannara plans to operationalize 12 more grow rooms, doubling capacity in four years

Company to launch vape category in Quebec, securing 20% of accepted SKUs

Cannara to invest in new processing center, funded by $10 mln loan from BMO

Result Drivers

MARKET SHARE EXPANSION - National market share rose to 3.81% in Fiscal 2025, up 32% year over year, with further growth to 4.1% in October 2025

CAPACITY EXPANSION - Activation of additional grow zones increased production capacity by 26%, achieving Fiscal 2026 target ahead of schedule

NEW PRODUCT LAUNCHES - Successful launch of new genetics and SKUs drove revenue growth

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
C$28.30 mln
Q4 EPS
C$0.04
Q4 Net Income
C$3.30 mln


Analyst Coverage

The one available analyst rating on the shares is "buy"

The average consensus recommendation for the healthcare facilities & services peer group is "buy"

Press Release: ID:nGNX9c2MKC

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)